Co-expression of foreign proteins tethered to HIV-1 envelope glycoprotein on the cell surface by introducing an intervening second membrane-spanning domain

PLoS ONE

Volumn 9, Issue 5, 2014, Pages

  Wang, Hongyun ^a   Li, Xiao ^a,b   Nakane, Shuhei ^a,c   Liu, Shujun ^a   Ishikawa, Hirohito ^a,c   Iwamoto, Aikichi ^c   Matsuda, Zene ^a,c  

^a INSTITUTE OF BIOPHYSICS   (China)

^b UNIVERSITY OF CHINESE ACADEMY OF SCIENCES   (China)

^c UNIVERSITY OF TOKYO   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

GLYCOPROTEIN; VIRUS ENVELOPE PROTEIN; GLYCOPROTEIN GP 41; MEMBRANE PROTEIN; SINGLE CHAIN FRAGMENT VARIABLE ANTIBODY;

AMINO ACID SEQUENCE; ANTIGEN BINDING; ARTICLE; CARBOXY TERMINAL SEQUENCE; CELL SURFACE; CODON; CONTROLLED STUDY; DNA SEQUENCE; FLOW CYTOMETRY; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; HYDROPHOBICITY; MEMBRANE PERMEABILITY; MOLECULAR CLONING; PROTEIN CLEAVAGE; PROTEIN DOMAIN; PROTEIN EXPRESSION; RESTRICTION SITE; SITE DIRECTED MUTAGENESIS; SPECIES DIVERSITY; BIOSYNTHESIS; CELL MEMBRANE; GENE EXPRESSION REGULATION; GENETICS; IMMUNOLOGY; ISOLATION AND PURIFICATION; MEMBRANE FUSION; METABOLISM; PROTEIN TERTIARY STRUCTURE; VIRUS ENTRY;

CELL MEMBRANE; GENE EXPRESSION REGULATION, VIRAL; HIV ENVELOPE PROTEIN GP41; HIV-1; HUMANS; MEMBRANE FUSION; MEMBRANE GLYCOPROTEINS; PROTEIN STRUCTURE, TERTIARY; SINGLE-CHAIN ANTIBODIES; VIRUS INTERNALIZATION;

EID: 84900542210     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0096790     Document Type: Article

References (54)

1. Dettenhofer M, Yu XF (2001) Characterization of the biosynthesis of human immunodeficiency virus type 1 Env from infected T-cells and the effects of glucose trimming of Env on virion infectivity. J Biol Chem 276: 5985-5991.
2. Otteken A, Earl PL, Moss B (1996) Folding, assembly, and intracellular trafficking of the human immunodeficiency virus type 1 envelope glycoprotein analyzed with monoclonal antibodies recognizing maturational intermediates. J Virol 70: 3407-3415. (Pubitemid 26157323)
3. Dash B, McIntosh A, Barrett W, Daniels R (1994) Deletion of a single N-linked glycosylation site from the transmembrane envelope protein of human immunodeficiency virus type 1 stops cleavage and transport of gp160 preventing env-mediated fusion. J Gen Virol 75 (Pt 6): 1389-1397. (Pubitemid 24174054)
4. Wyatt R, Sodroski J (1998) The HIV-1 envelope glycoproteins: fusogens, antigens, and immunogens. Science 280: 1884-1888. (Pubitemid 28299385)
5. Shang L, Yue L, Hunter E (2008) Role of the membrane-spanning domain of human immunodeficiency virus type 1 envelope glycoprotein in cell-cell fusion and virus infection. J Virol 82: 5417-5428. (Pubitemid 351705249)
6. Weiss CD (2003) HIV-1 gp41: mediator of fusion and target for inhibition. AIDS Rev 5: 214-221.
7. Eckert DM, Kim PS (2001) Mechanisms of viral membrane fusion and its inhibition. Annu Rev Biochem 70: 777-810. (Pubitemid 32662225)
8. Wu L, Gerard NP, Wyatt R, Choe H, Parolin C, et al. (1996) CD4-induced interaction of primary HIV-1 gp120 glycoproteins with the chemokine receptor CCR-5. Nature 384: 179-183. (Pubitemid 26386475)
9. Barre-Sinoussi F, Ross AL, Delfraissy JF (2013) Past, present and future: 30 years of HIV research. Nat Rev Microbiol 11: 877-883.
10. Zhang X, Wang X, Zhao D, Meng X, Zhao X, et al. (2011) Design and immunogenicity assessment of HIV-1 virus-like particles as a candidate vaccine. Sci China Life Sci 54: 1042-1047.
11. Garg H, Viard M, Jacobs A, Blumenthal R (2011) Targeting HIV-1 gp41-induced fusion and pathogenesis for anti-viral therapy. Curr Top Med Chem 11: 2947-2958.
12. Caffrey M (2011) HIV envelope: challenges and opportunities for development of entry inhibitors. Trends Microbiol 19: 191-197.
13. Stamatatos L, Morris L, Burton DR, Mascola JR (2009) Neutralizing antibodies generated during natural HIV-1 infection: good news for an HIV-1 vaccine? Nat Med 15: 866-870.
14. Liu S, Jiang S (2004) High throughput screening and characterization of HIV-1 entry inhibitors targeting gp41: theories and techniques. Curr Pharm Des 10: 1827-1843. (Pubitemid 38647464)
15. Kondo N, Miyauchi K, Meng F, Iwamoto A, Matsuda Z (2010) Conformational changes of the HIV-1 envelope protein during membrane fusion are inhibited by the replacement of its membrane-spanning domain. J Biol Chem 285: 14681-14688.
16. Ishikawa H, Meng F, Kondo N, Iwamoto A, Matsuda Z (2012) Generation of a dual-functional split-reporter protein for monitoring membrane fusion using self-associating split GFP. Protein Eng Des Sel 25: 813-820.
17. Teeranaipong P, Hosoya N, Kawana-Tachikawa A, Fujii T, Koibuchi T, et al. (2013) Development of a rapid cell-fusion-based phenotypic HIV-1 tropism assay. J Int AIDS Soc 16: 18723.
18. Long Y, Meng F, Kondo N, Iwamoto A, Matsuda Z (2011) Conserved arginine residue in the membrane-spanning domain of HIV-1 gp41 is required for efficient membrane fusion. Protein Cell 2: 369-376.
19. Atanasiu D, Saw WT, Gallagher JR, Hannah BP, Matsuda Z, et al. (2013) Dual split protein-based fusion assay reveals that mutations to herpes simplex virus (HSV) glycoprotein gB alter the kinetics of cell-cell fusion induced by HSV entry glycoproteins. J Virol 87: 11332-11345.
20. Lineberger JE, Danzeisen R, Hazuda DJ, Simon AJ, Miller MD (2002) Altering expression levels of human immunodeficiency virus type 1 gp120-gp41 affects efficiency but not kinetics of cell-cell fusion. J Virol 76: 3522-3533. (Pubitemid 34224553)
21. Yuste E, Reeves JD, Doms RW, Desrosiers RC (2004) Modulation of Env content in virions of simian immunodeficiency virus: correlation with cell surface expression and virion infectivity. J Virol 78: 6775-6785. (Pubitemid 38781514)
22. Mulampaka SN, Dixit NM (2011) Estimating the threshold surface density of Gp120-CCR5 complexes necessary for HIV-1 envelope-mediated cell-cell fusion. PLoS One 6: e19941.
23. Los GV, Encell LP, McDougall MG, Hartzell DD, Karassina N, et al. (2008) HaloTag: a novel protein labeling technology for cell imaging and protein analysis. ACS Chem Biol 3: 373-382.
24. Liu S, Kondo N, Long Y, Xiao D, Iwamoto A, et al. (2010) Membrane topology analysis of HIV-1 envelope glycoprotein gp41. Retrovirology 7: 100.
25. Sakaguchi N, Kimura T, Matsushita S, Fujimura S, Shibata J, et al. (2005) Generation of high-affinity antibody against T cell-dependent antigen in the Ganp gene-transgenic mouse. J Immunol 174: 4485-4494.
26. Pang W, Tam SC, Zheng YT (2009) Current peptide HIV type-1 fusion inhibitors. Antivir Chem Chemother 20: 1-18.
27. Sugaya M, Hartley O, Root MJ, Blauvelt A (2007) C34, a membrane fusion inhibitor, blocks HIV infection of langerhans cells and viral transmission to T cells. J Invest Dermatol 127: 1436-1443. (Pubitemid 46762990)
28. Gustchina E, Hummer G, Bewley CA, Clore GM (2005) Differential inhibition of HIV-1 and SIV envelope-mediated cell fusion by C34 peptides derived from the C-terminal heptad repeat of gp41 from diverse strains of HIV-1, HIV-2, and SIV. J Med Chem 48: 3036-3044. (Pubitemid 40548115)
29. Dogo-Isonagie C, Lam S, Gustchina E, Acharya P, Yang Y, et al. (2012) Peptides from second extracellular loop of C-C chemokine receptor type 5 (CCR5) inhibit diverse strains of HIV-1. J Biol Chem 287: 15076-15086.
30. Miyauchi K, Komano J, Yokomaku Y, Sugiura W, Yamamoto N, et al. (2005) Role of the specific amino acid sequence of the membrane-spanning domain of human immunodeficiency virus type 1 in membrane fusion. J Virol 79: 4720-4729. (Pubitemid 40464223)
31. Binley JM, Wrin T, Korber B, Zwick MB, Wang M, et al. (2004) Comprehensive cross-clade neutralization analysis of a panel of anti-human immunodeficiency virus type 1 monoclonal antibodies. J Virol 78: 13232-13252. (Pubitemid 39507829)
32. Sun ZY, Oh KJ, Kim M, Yu J, Brusic V, et al. (2008) HIV-1 broadly neutralizing antibody extracts its epitope from a kinked gp41 ectodomain region on the viral membrane. Immunity 28: 52-63.
33. Roben P, Moore JP, Thali M, Sodroski J, Barbas CF, 3rd, et al. (1994) Recognition properties of a panel of human recombinant Fab fragments to the CD4 binding site of gp120 that show differing abilities to neutralize human immunodeficiency virus type 1. J Virol 68: 4821-4828. (Pubitemid 24226546)
34. Kunert R, Ruker F, Katinger H (1998) Molecular characterization of five neutralizing anti-HIV type 1 antibodies: identification of nonconventional D segments in the human monoclonal antibodies 2G12 and 2F5. AIDS Res Hum Retroviruses 14: 1115-1128. (Pubitemid 28409164)
35. Alam SM, Scearce RM, Parks RJ, Plonk K, Plonk SG, et al. (2008) Human immunodeficiency virus type 1 gp41 antibodies that mask membrane proximal region epitopes: antibody binding kinetics, induction, and potential for regulation in acute infection. J Virol 82: 115-125. (Pubitemid 350309129)
36. Nicely NI, Dennison SM, Spicer L, Scearce RM, Kelsoe G, et al. (2010) Crystal structure of a non-neutralizing antibody to the HIV-1 gp41 membrane-proximal external region. Nat Struct Mol Biol 17: 1492-1494.
37. Zwick MB, Parren PW, Saphire EO, Church S, Wang M, et al. (2003) Molecular features of the broadly neutralizing immunoglobulin G1 b12 required for recognition of human immunodeficiency virus type 1 gp120. J Virol 77: 5863-5876. (Pubitemid 36538979)
38. Ofek G, McKee K, Yang Y, Yang ZY, Skinner J, et al. (2010) Relationship between antibody 2F5 neutralization of HIV-1 and hydrophobicity of its heavy chain third complementarity-determining region. J Virol 84: 2955-2962.
39. Lu M, Blacklow SC, Kim PS (1995) A trimeric structural domain of the HIV-1 transmembrane glycoprotein. Nat Struct Biol 2: 1075-1082.
40. Shu W, Liu J, Ji H, Radigen L, Jiang S, et al. (2000) Helical interactions in the HIV-1 gp41 core reveal structural basis for the inhibitory activity of gp41 peptides. Biochemistry 39: 1634-1642. (Pubitemid 30108955)
41. Lu M, Ji H, Shen S (1999) Subdomain folding and biological activity of the core structure from human immunodeficiency virus type 1 gp41: implications for viral membrane fusion. J Virol 73: 4433-4438. (Pubitemid 29189890)
42. Knappik A, Krebber C, Pluckthun A (1993) The effect of folding catalysts on the in vivo folding process of different antibody fragments expressed in Escherichia coli. Biotechnology (N Y) 11: 77-83. (Pubitemid 23013715)
43. Nieba L, Honegger A, Krebber C, Pluckthun A (1997) Disrupting the hydrophobic patches at the antibody variable/constant domain interface: improved in vivo folding and physical characterization of an engineered scFv fragment. Protein Eng 10: 435-444. (Pubitemid 27252635)
44. Jorgensen ML, Friis NA, Just J, Madsen P, Petersen SV, et al. (2014) Expression of single-chain variable fragments fused with the Fc-region of rabbit IgG in Leishmania tarentolae. Microb Cell Fact 13: 9.
45. Miller KD, Weaver-Feldhaus J, Gray SA, Siegel RW, Feldhaus MJ (2005) Production, purification, and characterization of human scFv antibodies expressed in Saccharomyces cerevisiae, Pichia pastoris, and Escherichia coli. Protein Expr Purif 42: 255-267. (Pubitemid 40985019)
46. Huarte N, Araujo A, Arranz R, Lorizate M, Quendler H, et al. (2012) Recognition of membrane-bound fusion-peptide/MPER complexes by the HIV-1 neutralizing 2F5 antibody: implications for anti-2F5 immunogenicity. PLoS One 7: e52740.
47. Guenaga J, Wyatt RT (2012) Structure-guided alterations of the gp41-directed HIV-1 broadly neutralizing antibody 2F5 reveal new properties regarding its neutralizing function. PLoS Pathog 8: e1002806.
48. Alam SM, Morelli M, Dennison SM, Liao HX, Zhang R, et al. (2009) Role of HIV membrane in neutralization by two broadly neutralizing antibodies. Proc Natl Acad Sci U S A 106: 20234-20239.
49. Wen M, Arora R, Wang H, Liu L, Kimata JT, et al. (2010) GPI-anchored single chain Fv-an effective way to capture transiently-exposed neutralization epitopes on HIV-1 envelope spike. Retrovirology 7: 79.
50. Chen SY, Khouri Y, Bagley J, Marasco WA (1994) Combined intra- and extracellular immunization against human immunodeficiency virus type 1 infection with a human anti-gp120 antibody. Proc Natl Acad Sci U S A 91: 5932-5936. (Pubitemid 24188256)
51. Zhou P, Goldstein S, Devadas K, Tewari D, Notkins AL (1998) Cells transfected with a non-neutralizing antibody gene are resistant to HIV infection: targeting the endoplasmic reticulum and trans-Golgi network. J Immunol 160: 1489-1496. (Pubitemid 28093452)
52. Lee SJ, Garza L, Yao J, Notkins AL, Zhou P (2004) A nonneutralizing anti-HIV-1 antibody turns into a neutralizing antibody when expressed on the surface of HIV-1-susceptible cells: a new way to fight HIV. J Immunol 173: 4618-4626. (Pubitemid 39280695)
53. Lee SJ, Arora R, Bull LM, Arduino RC, Garza L, et al. (2006) A nonneutralizing anti-HIV Type 1 antibody turns into a broad neutralizing antibody when expressed on the surface of HIV type 1-susceptible cells. II. Inhibition of HIV type 1 captured and transferred by DC-SIGN. AIDS Res Hum Retroviruses 22: 874-883. (Pubitemid 44757164)
54. Abacioglu YH, Fouts TR, Laman JD, Claassen E, Pincus SH, et al. (1994) Epitope mapping and topology of baculovirus-expressed HIV-1 gp160 determined with a panel of murine monoclonal antibodies. AIDS Res Hum Retroviruses 10: 371-381. (Pubitemid 24141211)